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Ischemic heart disease is a leading cause of death, and there is considerable imperative
to identify effective therapeutic interventions. Cardiomyocyte Ca2+ overload is a major
cause of ischemia and reperfusion injury, initiating a cascade of events culminating
in cardiomyocyte death, myocardial dysfunction, and occurrence of lethal arrhythmias.
Responsive to ﬂuctuations in intracellular Ca2+, Ca2+/calmodulin-dependent protein kinase
II (CaMKII) has emerged as an enticing therapeutic target in the management of ischemic
heart injury. CaMKII is activated early in ischemia and to a greater extent in the ﬁrst few
minutes of reperfusion, at a time when reperfusion arrhythmias are particularly prominent.
CaMKII phosphorylates and upregulates many of the key proteins involved in intracellular
Na+ and Ca2+ loading in ischemia and reperfusion. Experimentally, selective inhibition
of CaMKII activity reduces cardiomyocyte death and arrhythmic incidence post-ischemia.
New evidence is emerging that CaMKII actions in ischemia and reperfusion involve speciﬁc
splice variant targeted actions, selective and localized post-translational modiﬁcations, and
organelle-directed substrate interactions. A more complete mechanistic understanding of
CaMKII mode of action in ischemia and reperfusion is required to optimize intervention
opportunities. This review summarizes the current experimentally derived understanding
of CaMKII participation in mediating the pathophysiology of the heart in ischemia and in
reperfusion, and highlights priority future research directions.
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ISCHEMIA, REPERFUSION, AND Ca2+ OVERLOAD
Ischemic heart disease is a leading cause of mortality world-
wide. Though considerable advances have been made in the
understanding of the processes involved in the pathologi-
cal consequences of an ischemic event, effective therapeu-
tic management of this disease has been difﬁcult to achieve.
Ca2+/calmodulin-dependent protein kinase II (CaMKII) has
emerged as an enticing therapeutic target in the management
of ischemic heart injury, with considerable focus on its inhibi-
tion as a means for reducing injury arising from ischemia and
reperfusion.
A complex series of cardiomyocyte events occur during both
ischemia and reperfusion to culminate in an intracellular milieu
primed for activating CaMKII. Brieﬂy, insufﬁcient tissue perfu-
sion and oxygen availability in ischemia induce a shift to increased
reliance on anaerobic glycolysis for ATP generation, promoting
a build-up of metabolic intermediates including lactate and pro-
tons. This ionic shift stimulates the Na+/H+ exchanger (NHE)
to maintain physiological pH, which contributes to an accu-
mulation of intracellular Na+. The rise in intracellular Na+ is
exacerbated by a decrease in Na efﬂux, including a reduction
of Na+/K+-ATPase (NKA) activity that may be related to lower
ATP availability (van Echteld et al., 1991). Elevated cytosolic Na+
levels reduce the capacity for Ca2+ efﬂux via the Na+/Ca2+
exchanger (NCX) andpromote theCa2+ inﬂux“reverse”operating
mode of this transporter. Re-establishing coronary ﬂow (reperfu-
sion) is essential to ultimately allow any salvage of the ischemic
myocardium, but involves a signiﬁcant acute cardiomyocyte jeop-
ardy. Reperfusion rapidly restores the trans-sarcolemmal proton
gradient, exacerbating cellular Na+ accumulation (concomitant
with restoration of NKA activity) and eventually culminating in
Ca2+ overload. High cytosolic Ca2+ levels can have profound
negative effects on the cardiomyocyte in reperfusion (Murphy
and Steenbergen, 2008), inducing hypercontracture, electrical
instability, and contractile dysfunction. Ca2+ overload is a
major activator of the mitochondrial permeability transition pore
(mPTP) in reperfusion, a response associated with reactive oxygen
species (ROS) generation and the initiation of pro-death path-
ways (Halestrap, 2009). As CaMKII is highly sensitive to cytosolic
Ca2+ levels and regulates many channels and transporters impli-
cated in the steps leading to Ca2+ overload, there is considerable
scope for a CaMKII-mediated ampliﬁcation of high Ca2+ related
pathologies (see Figure 1). Furthermore, reports that CaMKII
is susceptible to oxidation (ox-CaMKII(Met281/2)), promoting
autonomous activation (Erickson et al., 2008; Palomeque et al.,
2009), suggests the sub-cellular environment in ischemia (acido-
sis, high cellular Ca2+) and reperfusion (Ca2+ overload, oxidative
stress) provides an optimal setting for rapid CaMKII activation –
and highlights the potential for intervention strategies targeting
CaMKII.
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FIGURE 1 | Overview of CaMKII activation and substrate interaction in
reperfusion. Post-ischemic restoration of coronary ﬂow re-establishes the
trans-sarcolemmal proton gradient and stimulates Na+/H+ exchange. This
promotes reverse-mode Na+/Ca2+ exchange and leads to intracellular Ca2+
overload. Ca2+-activated CaMKII upregulates many Ca2+-related
channels/transporters, further increasing cytosolic/mitochondrial Ca2+ levels,
and triggers the opening of the mitochondrial permeability transition pore. The
increase in Ca2+ and reactive oxygen species generation creates a positive
feedback on CaMKII and exacerbates ischemia/reperfusion injury. NCX,
Na+/Ca2+ exchanger; NHE, Na+/H+ exchanger; NKA, Na+/K+-ATPase;
LTCC, L-type Ca2+ channel; SR, sarcoplasmic reticulum; SERCA2a,
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase; PLB, phospholamban;
ROS, reactive oxygen species; mPTP, mitochondrial permeability transition
pore.
CaMKII IS RAPIDLY ACTIVATED IN ISCHEMIA AND
REPERFUSION
Seminal studies involving the characterization of CaMKII activa-
tion in ex vivo rodent hearts have mapped phospholamban (PLB)
phosphorylation at the CaMKII-speciﬁc site (P-PLB(Thr17)) as a
marker of CaMKII activation during acute ischemia and reperfu-
sion (Vittone et al., 2002). PLB is a regulatory accessory protein to
the sarcoplasmic reticulum (SR) Ca-ATPase (SERCA2a), which
exerts an inhibitory action on SERCA2a. PLB inhibition is
relieved by phosphorylation either by CaMKII or protein kinaseA.
Numerous subsequent studies, including our own, have shown P-
PLB(Thr17) to be brieﬂy elevated in early ischemia, peaking in the
initial 1–3min of reperfusion (Vittone et al., 2002; Said et al., 2003;
Valverde et al., 2006; Vila-Petroff et al., 2007; Salas et al., 2010) at
a time when hypercontracture and ventricular arrhythmias are
prevalent, before rapidly returning to basal activation level. This
elevated P-PLB(Thr17) occurs concomitantly with phosphoryla-
tion of other CaMKII substrates, including the SR Ca2+ release
channel (RyR2) and titin (Said et al., 2011; Hidalgo et al., 2013),
and can be blocked with CaMKII inhibitors, including KN93 and
AIP (Vittone et al., 2002; Said et al., 2003; Valverde et al., 2006;
Salas et al., 2010; Hidalgo et al., 2013). The source of Ca2+ stim-
ulating CaMKII activity differs in ischemia and reperfusion, with
Ca2+ entry through the L-type Ca2+ channel (LTCC) activating
CaMKII in ischemia and the NCX in reperfusion (blocked by
nifedipine and KB-R7943 respectively; Vittone et al., 2002). There
is evidence that CaMKII is activated both by phasic and tonic shifts
in cardiomyocyte intracellular free Ca2+ levels, and that local and
global Ca2+ signals have distinct effects (Wu et al., 2006). The
relative importance of each type of stimulus, and the additional
inﬂuence of post-translational modiﬁcations (e.g., oxidation of
the regulatory domain at Met281/282) in determining overall
CaMKII activation status in ischemia and reperfusion is not fully
elucidated.
CaMKII is also undoubtedly inﬂuenced by the intracellular aci-
dosis prevalent in ischemia and early reperfusion. Both CaMKII
autophosphorylation (P-CaMKII(Thr287)) and P-PLB(Thr17)
rapidly increase in acidic conditions, contributing to the recov-
ery of Ca2+ transients and contractile function that are initially
suppressed in acidic conditions (DeSantiago et al., 2004;Mundina-
Weilenmann et al., 2005; Vila-Petroff et al., 2010). Inhibiting
CaMKII suppresses PLB phosphorylation (and hence SERCA
activity), reducing SR Ca2+ uptake, causing cytsolic Ca2+ lev-
els to increase (affecting both systolic and diastolic function; see
(Mattiazzi andKranias, 2014)). An increase in P-CaMKII(Thr287)
has also been shown in the initial minutes of reperfusion (Said
et al., 2011), consistent with an elevated autonomous CaMKII
activity recently reported in in vivo mouse hearts subjected
to 1 h ischemia and 3 min reperfusion (Ling et al., 2013).
Interestingly, in contrast to the ex vivo studies, this elevated
activity in vivo was associated with a maintained increase in
P-PLB(Thr17) and RyR2 phosphorylation (P-RyR2(Ser2814))
throughout 120 min of subsequent reperfusion. The substantial
activation of CaMKII, which occurs in ischemia and reper-
fusion, would be expected to be an important determinant
of cardiomyocyte Ca2+ homeostasis and post-ischemic out-
comes.
CaMKII EXACERBATES ISCHEMIC INJURY
Increased intracellular Ca2+ correlates with the onset of irre-
versible injury in ischemia (Murphy and Steenbergen, 2008).
Inhibiting Ca entry through the LTCC has been shown to
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prevent/delay ischemic contracture onset and arrhythmias (Henry
et al., 1977; Curtis et al., 1984; Curtis and Walker, 1988). Con-
sidering CaMKII activation in early ischemia is linked with Ca
entry through the LTCC (Vittone et al., 2002), it may be pre-
dicted that CaMKII contributes to the cascade of events leading
to ischemic pathogenesis. We have shown that inhibiting CaMKII
with KN93 signiﬁcantly delays and blunts the extent of ischemic
contracture in ex vivo hearts subjected to 20 min of global
ischemia (Figure 2, (Bell et al., 2012)), suggesting a role for
CaMKII in ischemic myocyte Ca2+ loading and the onset of
irreversible injury. Inhibiting CaMKII also protects the heart
in a chronic in vivo ischemic setting, as demonstrated in stud-
ies utilizing two different CaMKII inhibitor rodent expression
models (CaMKII inhibitor peptide, AC3-I; mitochondrial-speciﬁc
CaMKII inhibitor protein, mtCaMKIIN). These studies found
that CaMKII promotes apoptosis in vivo (5 h post-myocardial
infarction)by exacerbating SRand/ormitochondrialCa2+ loading
(Yang et al., 2006; Joiner et al., 2012).
CaMKII ACTIONS IN REPERFUSION RECOVERY ARE
DEPENDENT ON ISCHEMIC DURATION
While initial studies assessing CaMKII in post-ischemic reperfu-
sion suggested that CaMKII activation may improve functional
recovery, subsequent studies have reported different ﬁndings and
suggest that the role played by CaMKII in the dysfunction asso-
ciated with reperfusion may be dependent on the duration of the
preceding ischemic insult. In isolated hearts subjected to 20 min
of ischemia, recovery of left ventricular developed pressure in
reperfusion was lower and diastolic dysfunction exacerbated in
the presence of KN93 (Vittone et al., 2002; Said et al., 2003). This
poor recovery was attributed to a disruption of CaMKII actions on
SRCa2+ uptake, as P-PLB(Thr17)was suppressed in early reperfu-
sion. Parallel experiments were conducted on hearts from mutant
mice expressing a PLB Thr to Ala mutation at amino acid residue
17 (Said et al., 2003), such that CaMKII-mediated phosphoryla-
tion at this site could not occur. The inhibitory action of PLB on
SERCA cannot be relieved in these mice. These hearts exhibited a
comparable contractile dysfunction in reperfusion aswas observed
inwild-type hearts treatedwithKN93. Taken together, these obser-
vations indicate that CaMKII can be beneﬁcial in reperfusion, aug-
menting SR Ca2+ uptake in reperfusion and enhancing cytosolic
Ca2+ clearance. However, with a longer ischemic challenge, these
beneﬁts attributed to CaMKII activation in modulating reperfu-
sion response are lost. Our further studies showed that extending
the duration of ischemia from 20 to 45 min in ex vivo hearts
profoundly affects how CaMKII inﬂuences reperfusion outcomes.
Indeed, treating hearts with KN93 signiﬁcantly reduces infarct size
and apoptosis, and improves functional recovery (Figure 3, Vila-
Petroff et al., 2007). Isolated cardiomyocyte survival is improved
in simulated ischemia and reperfusion with KN93 and AIP, to an
extent equivalent to the improvement achieved by inhibition either
of reverse-modeNCXor SRCa2+ cycling (SERCA2a and/or RyR2;
(Vila-Petroff et al., 2007; Salas et al., 2010)). These data suggests
that following shorter durations of ischemia, CaMKII activation
augments SERCA2a activity to enhance cytosolic Ca2+ removal
and reduce reperfusion injury/dysfunction. However, with more
extensive ischemia, the inﬂuence of CaMKII on SR Ca2+ release
FIGURE 2 | CaMKII inhibition reduces ischemic contracture and
reperfusion arrhythmias in male ex vivo hearts. Hearts subjected to
ischemia/reperfusion were treated with a CaMKII inhibitor (KN93). (A)The
amplitude of ischemic contracture was signiﬁcantly lower in the presence
of KN93, indicating CaMKII contributes to cardiomyocyte Ca2+ loading in
ischemia. (B) Analysis of ventricular pressure traces showed a substantial
reduction in the total duration of ventricular tachycardia and/or ﬁbrillation in
the ﬁrst ten minutes of reperfusion in KN93-treated hearts. Data are
expressed as mean ± SEM, *p < 0.05 vs. control. Reproduced with
permission (Elsevier, (Bell et al., 2012)).
mechanisms become more prominent in reperfusion, such that
SR Ca2+ leak exceeds the capacity of SERCA2a to reuptake
cytosolic Ca2+, and Ca2+-triggered reperfusion pathologies are
exacerbated.
Phosphorylation of the RyR2 (P-RyR2(Ser2814)) by CaMKII
increases the open probability of the SR Ca2+ release chan-
nel, augmenting SR Ca2+ leak and elevating cytosolic Ca2+
levels (Wehrens, 2011). A CaMKII-mediated increase in SR
Ca2+ release channel leakiness with elevation of cytosolic
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FIGURE 3 | Cell death in ischemia/reperfusion was suppressed by
CaMKII inhibition. (A) Assessment of TTC stained heart cross-sections
showed KN93 signiﬁcantly reduced infarct size in ischemia/reperfusion.
(B) Lower caspase 3 activation and less TUNEL positive cells in these
hearts showed KN93 also reduced apoptosis in reperfusion. Data are
expressed as mean ± SEM, *p < 0.05 vs. control; #p < 0.05 vs.
I/R. Reproduced with permission (Oxford Journals, (Vila-Petroff et al.,
2007)).
Ca2+ levels has important implications for mitochondrial func-
tion and myocyte viability. Studies indicate that inhibiting
CaMKII with KN93 may lower SR Ca2+ load to suppress
cytochrome C release and mitochondrial swelling in reperfusion
(Salas et al., 2010), both of which activate pro-death path-
ways in the heart. While this mitochondrial response partly
reﬂects the close beat-to-beat relationship between cytosolic and
mitochondrial Ca2+ levels (Robert et al., 2001), there is also
evidence that CaMKII directly inﬂuences mitochondrial oper-
ation in ischemia/reperfusion (Joiner et al., 2012). Hearts from
mice overexpressing a highly speciﬁc CaMKII inhibitor localized
to the mitochondria (mtCaMKIIN) exhibit less mitochondrial
injury and apoptosis, smaller infarcts, and recover contractile
function to a greater degree (vs. wild-type). Evidence suggests
the actions of CaMKII in the mitochondria are multi-faceted,
including a direct phosphorylation of the mitochondrial Ca2+
uniporter to increase the uniporter current (Joiner et al., 2012).
This would increase mitochondrial Ca levels, leading to mPTP
opening and dissipation of the mitochondrial inner membrane
potential. Furthermore, a resultant increase in ROS produc-
tion would be expected to exacerbate CaMKII activation and
actions.
Beyond these mitochondrial actions, recent data suggests that
the role of CaMKII in exacerbating ischemia and reperfusion
pathologies is not restricted to disrupting Ca2+ homeostasis at the
SR andmitochondria, andmay extend to direct pro-inﬂammatory
actions. Indeed, cardiac-speciﬁc deletion of CaMKIIδ reduces
chronic post-ischemic reperfusion (24 h) inﬂammation and injury
in vivo, diminishing IκBα degradation and NF-κB activation
(Ling et al., 2013). NF-κB is well recognized as an important
pro-inﬂammatory mediator in ischemia and reperfusion (Van der
Heiden et al., 2010), and this more recent evidence of a direct
stimulatory action on NF-κB and the inﬂammatory response
extends understanding of CaMKII as a regulator of the ischemic
myocardial stress response.
CaMKII MODULATION OF RyR2 DETERMINES REPERFUSION
ARRHYTHMOGENESIS
CaMKII has been implicated in generating arrhythmias in numer-
ous different cardiopathologies (Rokita and Anderson, 2012),
primarily attributed to its stimulatory action on RyR2. Aug-
mented P-RyR2(Ser2814) increases SR Ca2+ leak and promotes
Ca2+ extrusion though Na+/Ca2+ exchange. This electrogenic
process partially depolarizes the cell, increasing the likelihood
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of spontaneous contraction. Experimentally, inhibiting CaMKII
reduces spontaneous beats in post-acidotic and pro-oxidant envi-
ronments (Said et al., 2008; Xie et al., 2009), both of which play
a central role in the pathogenesis of ischemia and reperfusion
injury. We have shown that CaMKII inhibition with KN93 sup-
presses the incidenceof lethal arrhythmias (ventricular tachycardia
and/or ﬁbrillation) in early reperfusion through an unknown
mechanism (Figure 2, (Bell et al., 2012)). There are reservations
regarding the use of KN93 as a CaMKII inhibitor, due to its
reported non-selective actions on other transporters including the
L-type Ca and potassium channels. The occurrence of these non-
selective actions depends on treatment duration and dose (Gao
et al., 2006; Rezazadeh et al., 2006). Studies utilizing a similar
isolated heart preparation and CaMKII inhibition protocol also
report an antiarrhythmic action with KN93, that is absent in par-
allel studies using the inactive analog, KN92 (Said et al., 2011).
This suggests a legitimate role for CaMKII in promoting arrhyth-
mias in reperfusion. Indeed, these studies showed that inhibiting
CaMKII reduces incidence of ventricular premature beats, pri-
marily through a suppression of CaMKII mediated SR Ca release
channel phosphorylation (at RyR2(Ser2814)) and associated SR
Ca leak (Said et al., 2011). CaMKII-dependent phosphorylation
of the SR Ca channel increases channel open probability, lowering
the SR Ca threshold and increasing the propensity for Ca waves
(Curran et al., 2010; Stokke et al., 2011). This ability to modulate
the SR Ca channel and its inﬂuence on self-propagating SR Ca
release indicates that inhibiting CaMKII at the time of reperfu-
sion may have therapeutic potential as a ﬁrst-line antiarrhythmic
agent.
It should be noted that CaMKII actions are dependent on the
balance of substrate phoshorylation by CaMKII and dephospho-
rylation by associated protein phosphatases (PPs) in the myocyte,
including PP1 and PP2a. Downstream Ca handling protein tar-
gets of CaMKII are regulated by these phosphatases. Indeed, PP1
is reported to form part of a multimeric complex in the regu-
lation of PLB (as reviewed previously, (Mattiazzi and Kranias,
2014)), which may inﬂuence CaMKII-mediated phosphorylation,
cardiac contractility and the ischemic stress response (Nicolaou
et al., 2009). The balance between CaMKII and phosphatase
activation will therefore clearly inﬂuence the relative actions of
CaMKII in the heart. Furthermore, CaMKII autophosphoryla-
tion is itself regulated by phosphatases including PP1, PP2a, and
CaMK phosphatase (CaMKP; Ishida et al., 2008), though little
is known about how these regulate myocardial CaMKII. Very
recently, it has been shown that the CaMKP is expressed in the
heart, and changes in response to systemic loading (Previlon
et al., 2014). Interestingly, basal CaMKP levels were higher in
females (vs. males) and loading-induced CaMKP expressions were
sex-speciﬁc. It is important to highlight that all the CaMKII stud-
ies discussed above have involved experimental studies of male
rodent cardiac tissues/myocytes only. There are well-described
sex differences in excitation–contraction coupling and cardiomy-
ocyte Ca2+ handling processes, and the myocardial response
to ischemia and reperfusion (Bell et al., 2013a). Limited exper-
imental evidence indicates that CaMKII activity is inﬂuenced
by sex and sex steroids (Konhilas et al., 2004), and that estro-
gen may suppress CaMKII actions in ischemia and reperfusion
(Ma et al., 2009). However, our very recent data show that
P-CaMKII(Thr287) and P-PLB(Thr17) levels are augmented in
reperfused female hearts (vs. male controls), despite these hearts
exhibiting fewer arrhythmias in reperfusion (Bell et al., 2013b).
These ﬁndings suggest that CaMKII is not always pro-arrhythmic
in reperfusion, and support the concept that CaMKII can have
both beneﬁcial and detrimental actions in reperfusion which may
depend on the sub-cellular environment in which the enzyme is
activated.
EVIDENCE FOR A BENEFICIAL ROLE FOR CaMKII IN
ISCHEMIA AND REPERFUSION
Though considerable evidence indicates a deleterious role for
CaMKII in ischemia and reperfusion, a growing body of work sug-
gests there may be settings where CaMKII is beneﬁcial. CaMKII
has been implicated in the cardioprotection afforded by ischemic
preconditioning (Osada et al., 2000; Benter et al., 2005; Li et al.,
2007) and may form part of the signaling cascade that culmi-
nates in opening of the end-effector KATP channels (Li et al., 2007;
Chai et al., 2011; Zhang et al., 2014). Other data also suggest that
CaMKIIδ splice variants may exert differential responses in the
pathological environments prevalent in ischemia and reperfusion.
Peng et al. (2010) showed that CaMKIIδB has been shown to pro-
tect against apoptosis in hydrogen peroxide-treated neonatal rat
ventricular myocytes, through an upregulation of heat shock pro-
tein 70 (Peng et al., 2010). However, expression of CaMKIIδB
decreases in these conditions over a period of hours, in direct
contrast to CaMKIIδC, such that a reduction of inﬂuence on
ischemic resilience would be expected to reduce with time (Peng
et al., 2010). Interestingly, preliminary reports indicate that hearts
from transgenic mice selectively overexpressing CaMKIIδB are less
susceptible to ischemia and reperfusion injury (Gray et al., 2013),
corroborating the notion of a cardioprotective action for this splice
variant in ischemia/reperfusion.
As outlined above, CaMKII can provide important inotropic
support to maintain contractile function in stunned hearts sub-
jected to a brief ischemic challenge. An important body of
experimental work supports the view that CaMKII actions can
transition from conferring beneﬁt to liability in a manner which
reﬂects the myocyte capacity to balance relative SR Ca2+ uptake
and leak. CaMKII “protection” is understood to be forfeited when
the greater probability of spontaneous SR Ca2+ release outweighs
the enhancement of cytosolic Ca2+ clearance (Mattiazzi and Kra-
nias, 2011). Themechanisms responsible are not fully understood,
but the extent of ox-CaMKII(Met281/2) generationmay be impli-
cated. With extended ischemia, it may be that an increase in
ROS production in reperfusion further augments CaMKII activa-
tion and actions, possibly through greater ox-CaMKII(Met281/2)
generation. As ox-CaMKII(Met281/2) increases P-RyR2(Ser2814)
phosphorylation (Ho et al., 2014), an increase in SR Ca2+ leak
would be expected. This may be a critical factor in promot-
ing injury in reperfusion. Our very recent ﬁndings suggest that
speciﬁc post-translational modiﬁcations of CaMKII determine
substrate speciﬁcity, and that in contrast to P-CaMKII(Thr287),
ox-CaMKII(Met281/2) selectively phosphorylates the RyR2 and
not PLB (Bell et al., 2014). Augmented SRCa uptake would be pre-
dicted to increase SR Ca2+ load (Shannon et al., 2002; Venetucci
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et al., 2007). With a concomitant increase in P-RyR2(Ser2814),
this could augment SR Ca2+ leak; an effect that may be offset if
the Ca2+ levels at the RyR2 cytoplasmic domain are sufﬁciently
reduced (Laver, 2009).
In summary, CaMKII is a crucial regulatory intermediate in
ischemia and reperfusion injury. CaMKII is relatively quiescent
under basal conditions, but displays considerable capacity to exac-
erbate Ca2+ mismanagement and mitochondrial dysfunction in
response to ischemic changes in cellular Ca2+ and redox status.
Thus, there is potential for CaMKII inhibitor utilization as a
prophylactic therapeutic intervention for “at risk” patients with
ischemic heart disease. Conversely, conﬂicting reports suggest
that in other circumstances maintained CaMKII activation can
improve reperfusion recovery. To optimize and tailor therapeutic
strategies involving manipulation of CaMKII activation, it is clear
that further mechanistic studies are required to fully understand
the nuances of CaMKII response in a range of pathophysiologic
settings.
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